近日，国际著名杂志《内科学年鉴》Archives of internal medicine刊登了研究人员的最新研究成果“Helicobacter pylori Eradication in Functional Dyspepsia: HEROES Trial。”，研究人员研究表明，根除幽门螺杆菌可能会缓解消化不良患者的一些症状，即使未发现其有溃疡。
对于那些不能通过调整饮食、锻炼和减轻压力之类的生活方式改变而得到改善的患者，巴西研究人员提示胃灼热药物和抗生素联用也许值得尝试。研究人员将404例功能性消化不良患者随机分入两组：一组接受奥美拉唑单药治疗，另一组接受奥美拉唑联合阿莫西林和克拉霉素联合治疗，为期10天。
一年后，抗生素组中49%的患者表示其症状改善了至少50%，与之相比，对照组的这一比例为37%。
巴西马佐莱尼医院路易斯埃德蒙博士和同事进行的研究报告表明，8名患者需要抗生素治疗，其中1名患者会出现上述比例的改善。据研究人员表示，关于清除幽门螺杆菌的影响，较早的研究得出的结论不明确，影响了多达一半的世界人口。
然而他们的研究结果仅来自于一家医院，其它地方可能并不支持。他们建议检测非溃疡性胃痛患者体内的细菌并且予以治疗。但他们还呼吁进行更多的研究，以检验该措施是否划算。
加拿大安大略省汉密尔顿麦克马斯大学Moyyedi博士的一篇评论指出，现在有充分的证据证明清除幽门螺杆菌对小部分患者有用。
他总结道“将要面临的挑战是确定这一影响的潜在机制，以便我们可以前进一步，更好地治疗这种医疗费用昂贵的常见病。（生物谷Bioon.com）
延伸阅读：
Nature：幽门螺旋杆菌适应多变条件“主转录组”确定
幽门螺旋杆菌可“变形”感染不同血型者
J. Med. Chem.：发现抗幽门螺旋杆菌活性化合物
doi:10.1001/archinternmed.2011.533
PMC:
PMID:
Helicobacter pylori Eradication in Functional Dyspepsia: HEROES Trial.
Mazzoleni LE,Heck R,Dahmer FD,et al.
Background Eradication of Helicobacter pylori in patients with functional dyspepsia continues to be a matter of debate. We studied eradication effects on symptoms and quality of life of primary care patients. Methods Helicobacter pylori –positive adult patients with functional dyspepsia meeting the Rome III International Consensus criteria were randomly assigned to receive omeprazole, amoxicillin trihydrate, and clarithromycin, or omeprazole plus placebo for 10 days. Endoscopy and H pylori tests were performed at screening and at 12 months. Outcome measures were at least 50% symptomatic improvement at 12 months using a validated disease-specific questionnaire (primary end point), patient global assessment of symptoms, and quality of life. Results We randomly assigned 404 patients (78.7% were women; mean age, 46.1 years); 201 were assigned to be treated with antibiotics (antibiotics group) and 203 to a control group. A total of 389 patients (96.3%) completed the study. The proportion of patients who achieved the primary outcome was 49.0% (94 of 192) in the antibiotics group and 36.5% (72 of 197) in the control group (P = .01; number needed to treat, 8). In the patient global assessment of symptoms, 78.1% in the antibiotics group (157 of 201) answered that they were better symptomatically, and 67.5% in the control group (137 of 203) said that they were better (P = .02). The antibiotics group had a significantly larger increase in their mean (SD) Medical Outcomes Study 36-Item Short Form Health Survey physical component summary scores than the control group did (4.15 [8.5] vs 2.2 [8.1]; P = .02). Conclusion Helicobacter pylori eradication provided significant benefits to primary care patients with functional dyspepsia.
